国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
INTERNATIONAL JOURNAL OF UROLOGY AND NEPHROLOGY
2011年
5期
618-621
,共4页
前列腺肿瘤%多态现象(遗传学)
前列腺腫瘤%多態現象(遺傳學)
전렬선종류%다태현상(유전학)
Prostate Neoplasms%Polymorphism (Genetics)
目的 探讨类固醇5a-还原酶Ⅱ (SRD5a2)基因89位点多态性与亚洲男性前列腺癌易感性的关系。方法 检索PubMed、中国知网、万方、维普数据库，获取SRD5a2基因89位点多态性与亚洲男性前列腺癌易感性的病例-对照研究。以前列腺癌组与对照组人群基因型分布的OR值为效应指标，采用固定或随机效应模型进行合并分析，并进行偏倚评估，应用Stata10.0软件进行统计学处理。结果 共纳入文献10篇，病例-对照研究8项，累计前列腺癌病例1141例，对照1423例。总的来说，与等位基因V相比，L等位基因合并的OR(95％CI)为0.96 (0.91 -1.02)；与野生基因型VV相比，LL、LV和LL +LV基因型合并的OR(95％CI)分别为0.94(0.84 ～ 1.04)、0.96(0.89 ～1.03)和0.97（0.92～1.02）；隐性模型(LL vs. LV+VV)合并的0R(95％CI)为0.95（0.84～1.09）。而在对照来源于医院的亚分组中，我们发现携带LV基因型的个体与携带VV基因型的个体相比，其患前列腺癌的风险降低合并的OR(95％CI)为0.86(0.75～1.00)。结论总体上，SRD5a2基因89位点变异与亚洲男性个体患前列腺癌的易感性无关，而在在对照来源为医院的研究中，能降低亚洲男性患前列腺癌的风险性。
目的 探討類固醇5a-還原酶Ⅱ (SRD5a2)基因89位點多態性與亞洲男性前列腺癌易感性的關繫。方法 檢索PubMed、中國知網、萬方、維普數據庫，穫取SRD5a2基因89位點多態性與亞洲男性前列腺癌易感性的病例-對照研究。以前列腺癌組與對照組人群基因型分佈的OR值為效應指標，採用固定或隨機效應模型進行閤併分析，併進行偏倚評估，應用Stata10.0軟件進行統計學處理。結果 共納入文獻10篇，病例-對照研究8項，纍計前列腺癌病例1141例，對照1423例。總的來說，與等位基因V相比，L等位基因閤併的OR(95％CI)為0.96 (0.91 -1.02)；與野生基因型VV相比，LL、LV和LL +LV基因型閤併的OR(95％CI)分彆為0.94(0.84 ～ 1.04)、0.96(0.89 ～1.03)和0.97（0.92～1.02）；隱性模型(LL vs. LV+VV)閤併的0R(95％CI)為0.95（0.84～1.09）。而在對照來源于醫院的亞分組中，我們髮現攜帶LV基因型的箇體與攜帶VV基因型的箇體相比，其患前列腺癌的風險降低閤併的OR(95％CI)為0.86(0.75～1.00)。結論總體上，SRD5a2基因89位點變異與亞洲男性箇體患前列腺癌的易感性無關，而在在對照來源為醫院的研究中，能降低亞洲男性患前列腺癌的風險性。
목적 탐토류고순5a-환원매Ⅱ (SRD5a2)기인89위점다태성여아주남성전렬선암역감성적관계。방법 검색PubMed、중국지망、만방、유보수거고，획취SRD5a2기인89위점다태성여아주남성전렬선암역감성적병례-대조연구。이전렬선암조여대조조인군기인형분포적OR치위효응지표，채용고정혹수궤효응모형진행합병분석，병진행편의평고，응용Stata10.0연건진행통계학처리。결과 공납입문헌10편，병례-대조연구8항，루계전렬선암병례1141례，대조1423례。총적래설，여등위기인V상비，L등위기인합병적OR(95％CI)위0.96 (0.91 -1.02)；여야생기인형VV상비，LL、LV화LL +LV기인형합병적OR(95％CI)분별위0.94(0.84 ～ 1.04)、0.96(0.89 ～1.03)화0.97（0.92～1.02）；은성모형(LL vs. LV+VV)합병적0R(95％CI)위0.95（0.84～1.09）。이재대조래원우의원적아분조중，아문발현휴대LV기인형적개체여휴대VV기인형적개체상비，기환전렬선암적풍험강저합병적OR(95％CI)위0.86(0.75～1.00)。결론총체상，SRD5a2기인89위점변이여아주남성개체환전렬선암적역감성무관，이재재대조래원위의원적연구중，능강저아주남성환전렬선암적풍험성。
Objectives To investigate the relationship between steroid 5 - a - reductase type 2 (SRD5a2)gene V89L polymorphism and genetic susceptibility to prostate cancer in Asian man. Methods PubMed, China National Knowledge Infrastructure ( CNKI), Wanfang database and Weipu database were searched for published case -control studies investigating the association between SRDSa2 V89L polymorphism and susceptibility to prostate cancer in Asian man. The odds ratio was calculated to evaluate the genotypes of prostate cancer patients and controls subjects. Fixed or random effect models were selected for pooled odds ratio calculation. Publication bias was assessed. All statistical analysis was conducted with Stata 10.0 software. Results A total of eight case - control studies involving 1141 prostate cancer patients and 1423 controls were analyzed in our study. Overall, compared with the V allele, the pooled odds ratio (OR) [ and 95％ confidence interval (CI) ] for L allele was 0.96 (0.91 ～ 1.01 ) ; compared with the wide - type genotype ( homozygote VV), the pooled Ot (95％ CI) for LL, LV and LL + LVgenotypes was 0. 94 (0.84 ～ 1.04 ) , 0. 95 ( 0. 89 ～ 1.02 ) and 0. 96 ( 0. 92 ～ 1. 01 ), respectively. In the recessive genetic model, the pooled OR ( 95 ％ CI) was 0.96 ( 0.84 ～ 1.09 ). However, in the source of control subgroup, individuals carried LV genotype may decrease prostate cancer risk compared to VV genotype. Conclusions Totally, SRD5a2 V89L polymorphism may not be associated with susceptibility of prostate cancer in Asian man, however,in the source of control subgroup, a decreased risk was detected between this polymorphism and prostate cancer.
